1. Introduction

Dark web biologics trafficking refers to the unlawful online advertising, sale, purchase, distribution, importation or exportation of biological products through concealed online marketplaces and related digital channels. Such products may include counterfeit vaccines, unapproved gene therapies, falsified biological medicines, unlawfully obtained human tissues, blood products, cell therapies, laboratory-derived biological materials and temperature-sensitive therapeutic products diverted from legitimate supply chains.

The legal challenge is that these transactions combine several different forms of wrongdoing: pharmaceutical crime, cybercrime, customs violations, financial concealment, fraud, and potentially serious threats to public health.

INTERPOL identifies illicit and counterfeit medicines sold through unauthorized online channels as a global public-health concern. Its Operation Pangea XVII, conducted from December 2024 to May 2025 across 90 countries, resulted in 50 million doses of illicit pharmaceuticals seized and 769 suspects arrested. These figures concern illicit pharmaceuticals generally, not biologics or dark-web transactions exclusively.

Interpol

Central legal question: How can authorities identify anonymous sellers, establish the biological product's true composition and origin, preserve admissible digital evidence, coordinate across borders, and hold the responsible parties accountable without obstructing lawful biomedical research or legitimate patient access?

2. Meaning and legal scope

ImmunityBio secures exclusive U.S. rights to Tokyo BCG | IBRX Stock News

A. Counterfeit and falsified biologics

Products falsely presented as genuine vaccines, monoclonal antibodies, insulin, blood-derived medicines or other biological therapies. Enforcement focuses on product authenticity, fraud, regulatory authorization and risks to patients.

Importing Injectable Medicines from India: Cold Chain Logistics & Safety Explained - CrossVia Global

B. Diverted or improperly stored biologics

Genuine products may be stolen, resold without authorization, or distributed after a breach of required storage conditions. A genuine product can still be unsafe or unsuitable for use.

Video: Logistics Leaders: Connecting Cell and Gene Therapies to Patients

C. Illicit human-derived materials and advanced therapies

Certain transactions may involve unlawfully obtained tissues, cells or other human-derived materials, or gene and cell therapies supplied outside applicable regulatory controls. Consent, donor protection, traceability and biosafety may be central issues.

These categories must not be treated as legally interchangeable. A product can be unapproved without being counterfeit; a genuine product can be diverted; and a biological sample can raise consent or ownership issues without necessarily constituting an illegal medicine.

The term dark web describes a means of accessing or concealing online activity. It does not itself establish a criminal offence. Liability depends on the conduct, the product, applicable law and the evidence.

3. Principal enforcement challenges

3.1 Anonymous identities and attribution

Sellers may use aliases, concealed communication channels, intermediaries and cryptocurrency. Investigators must distinguish between:

The person controlling a seller account.

The person manufacturing or supplying the product.

The person arranging payment and delivery.

An intermediary who knowingly participates in unlawful conduct.

A legitimate buyer, researcher or patient who may not know that a product is falsified.

An online username alone ordinarily does not establish who committed the offence. Attribution may require corroboration from account records, seized devices, transaction records, witness testimony, shipping evidence and other independently obtained material.

3.2 Establishing the product's biological identity

Biologics are more difficult to characterize than many ordinary counterfeit goods because their identity, potency and safety can depend on complex molecular structures, manufacturing conditions, purity and storage history.

Enforcement agencies may need qualified laboratories to determine:

Whether the product contains the claimed active ingredient.

Whether it is contaminated, degraded or substituted.

Whether the packaging and batch identifiers are authentic.

Whether the product was manufactured under required quality controls.

Whether a cold-chain failure makes it unsuitable for its intended use.

A laboratory result showing that a product is defective does not, by itself, prove that a particular defendant knowingly trafficked it. The prosecution must also establish the relevant elements of the alleged offence.

3.3 Cross-border jurisdiction

A single transaction may involve a seller in one country, a hosting service in another, payment infrastructure in a third, and a recipient in a fourth. The countries may have different definitions of counterfeit medicines, different evidentiary standards and different extradition requirements.

This creates questions about:

Which country may prosecute the seller.

Whether local law criminalizes the conduct.

How electronic evidence may lawfully be obtained abroad.

Whether an overseas search or seizure can be recognized in domestic proceedings.

Whether extradition, mutual legal assistance or coordinated prosecution is appropriate.

3.4 Biological supply-chain traceability

Authorities may struggle to reconstruct the chain from manufacturer to wholesaler, distributor, online seller and final recipient. Inadequate records can impede product recalls, identify neither the source of contamination nor the extent of exposure, and make it harder to distinguish deliberate diversion from administrative failure.

3.5 Patient safety and delayed harm

An ineffective vaccine, contaminated biological medicine or improperly stored therapy may cause harm long after the transaction. This complicates causation, victim identification, medical evidence and the calculation of compensation.

In some cases, the harm may be uncertain or emerge gradually. Courts must distinguish scientifically supported risks from speculation and determine whether the defendant's conduct caused or materially contributed to the injury under the applicable legal standard.

3.6 Digital evidence and admissibility

Digital evidence can include marketplace listings, transaction histories, private messages, account records, shipping documentation and records obtained from service providers. Investigators must establish authenticity, integrity, lawful acquisition and the connection between the evidence and the accused.

Relevant questions include:

Was the evidence collected under valid legal authority?

Can the original source and integrity of the data be established?

Are timestamps, account attribution and transaction records reliable?

Were applicable rules on electronic evidence and cross-border disclosure followed?

Can the defence inspect and challenge the prosecution's technical evidence?

A takedown of a website is not equivalent to proof of every user's criminal involvement. Evidence must connect the alleged conduct to the particular defendant.

3.7 Cryptocurrency and financial investigations

Digital payments can obscure the relationship between the seller, intermediary and recipient. Investigators may need to combine financial records with communications, delivery records and evidence of beneficial ownership.

The existence of cryptocurrency payments is not itself evidence of a crime. Prosecutors must prove the relevant underlying offence and, where money laundering is alleged, the required knowledge and other statutory elements.

3.8 Distinguishing criminal conduct from legitimate activity

Biomedical researchers, patients, collectors of scientific materials and licensed distributors may engage in legitimate activities involving biological products. Overbroad enforcement could interfere with lawful research, compassionate-use treatment or legitimate scientific exchange.

The legal response should therefore be based on product classification, regulatory status, consent, the nature of the transaction and the accused's knowledge—not merely the use of encrypted communications or an anonymous marketplace.

4. Applicable legal frameworks in India

For an Indian investigation, the applicable provisions depend on whether the product is a drug, a biological medicine, a human tissue or cell, a controlled substance, or another regulated biological material.

These laws operate alongside applicable licensing conditions, product-specific regulations and state or central enforcement powers. The precise charging provisions should be checked against the facts and the law in force when the alleged conduct occurred.

4.1 Key Indian enforcement considerations

First, regulatory classification: Authorities must determine whether the material falls within the applicable statutory definition of a drug or another regulated product. A laboratory specimen, a human tissue sample and a finished therapeutic product do not automatically have identical legal status.

Second, authorization: The prosecution may need to establish the required licence, approval or permission and demonstrate how the conduct contravened the applicable requirement.

Third, electronic proof: Digital evidence must satisfy the applicable evidentiary requirements. Account ownership, message authenticity and transaction attribution should not be assumed.

Fourth, cross-border cooperation: Investigators may require lawful assistance from foreign authorities or service providers to obtain records, identify suspects and establish the movement of products and money.

Fifth, public-health response: Seizure, testing, notification and recall measures may be necessary even before criminal responsibility has been finally determined, provided the relevant authorities act within their legal powers.

5. Important case laws and their relevance

A significant limitation must be stated at the outset: the following cases provide relevant principles for prosecuting counterfeit medicines, online trafficking and electronic evidence. They should not all be described as direct precedents concerning dark-web trafficking in biologics.

Case 1: United States v. Wala (2026)

U.S. Court of Appeals for the Sixth Circuit · No. 24-6021 · February 4, 2026

Facts: Omar Wala participated in a conspiracy involving the manufacture and distribution of approximately 16.1 million counterfeit alprazolam pills through dark-web and other channels. The counterfeit pills imitated legitimate pharmaceutical products, and payments included cryptocurrency.

Legal issue: Whether the sentencing court reasonably calculated financial loss and applied enhancements relating to victims, mass marketing and the risk of death or serious bodily injury.

Decision: The Sixth Circuit affirmed the sentence, upholding the district court's loss calculation and relevant sentencing enhancements on the evidentiary record.

Justia Law+1

Relevance to biologics trafficking:

Counterfeit presentation can deceive ultimate consumers even when an intermediary knows the product is fraudulent.

Financial loss may extend beyond the immediate wholesale transaction where the evidence supports that conclusion.

The foreseeable risks associated with counterfeit health products may aggravate sentencing.

Digital anonymity does not eliminate the possibility of proving a criminal conspiracy.

Limitation: This case involved counterfeit drugs, not biological medicines specifically. Its reasoning is potentially instructive by analogy, but it does not establish a biologics-specific legal rule.

Case 2: United States v. Tagg, 886 F.3d 579 (6th Cir. 2018)

Legal principle: The Sixth Circuit discussed the dark web as an online environment that can provide a degree of anonymity to users.

Relevance: Investigators must establish a reliable evidentiary connection between an online identity, the accused and the relevant criminal conduct. An alias or the use of an anonymity-oriented network is not, by itself, proof of guilt.

This principle is particularly important when prosecuting a person accused of selling falsified biological medicines through an anonymous marketplace. The prosecution still needs evidence establishing the required elements of the offence. The case is also discussed in the subsequent Wala decision.

Justia Law

Case 3: Arjun Panditrao Khotkar v. Kailash Kushanrao Gorantyal, (2020) 7 SCC 1

Supreme Court of India · Decided July 14, 2020

Facts: The case concerned the admissibility of electronic records, including video recordings, in election proceedings.

Legal issue: What requirements govern the admission of electronic records produced as secondary evidence under the former Section 65B of the Indian Evidence Act, 1872?

Decision: The Supreme Court reaffirmed the requirements governing electronic evidence under Section 65B, including the applicable certificate requirements for secondary electronic evidence, subject to the judgment's qualifications.

WBJA+1

Application to dark-web investigations: Marketplace records, downloaded messages, transaction histories and copied digital files must be collected and presented in compliance with the applicable law.

There is an important statutory update: the Bharatiya Sakshya Adhiniyam, 2023, came into force on July 1, 2024, replacing the former Evidence Act for proceedings governed by the new legislation. Consequently, current proceedings require analysis under the applicable provisions of the 2023 Act, alongside relevant precedents and transitional rules.

The broader lesson remains that digital evidence must be authentic, legally admissible and sufficiently connected to the alleged offence.

Case 4: Anvar P.V. v. P.K. Basheer, (2014) 10 SCC 473

Supreme Court of India · Decided September 18, 2014

Legal principle: The Court established an important framework for proving electronic records under Section 65B of the former Indian Evidence Act.

Relevance: In a biologics-trafficking prosecution, investigators may possess digital copies of seller communications, online advertisements or payment records. The prosecution must establish admissibility under the law applicable to the proceedings, rather than assume that a screenshot or printout automatically proves its contents.

This decision should be read together with Arjun Panditrao, which clarified the governing Section 65B principles.

Indian Kanoon+1

Case 5: United States v. Gordon — counterfeit drugs purchased through the dark web

U.S. District Court for the Eastern District of Pennsylvania · Sentencing announced March 10, 2020

Facts: Michael Gordon participated in a scheme to obtain counterfeit Xanax through the dark web and resell it. The investigation involved efforts to conceal the distribution activity.

Outcome: Gordon was sentenced to 20 years' imprisonment for conspiracy involving counterfeit goods and money laundering, and was ordered to pay restitution and forfeit assets.

United States Department of Justice

Relevance: The case demonstrates how pharmaceutical counterfeiting, distribution, concealment and financial offences can be addressed together.

Limitation: It was not a biologics-trafficking prosecution, and its sentence reflects the applicable U.S. law and facts of that case.

6. How the cases fit together

These authorities offer a useful comparative framework. They do not replace analysis of the exact Indian statutory offence, the biological product's classification or the jurisdiction in which the conduct occurred.

7. International enforcement and cooperation

Dark-web biologics trafficking often requires cooperation among pharmaceutical regulators, customs agencies, cybercrime investigators, financial intelligence units and public-health authorities.

INTERPOL

Coordinates international operations targeting counterfeit and illicit medicines and facilitates cooperation among national law-enforcement agencies. Operation Pangea provides an example of coordinated action against illicit pharmaceutical distribution.

Interpol

Mutual legal assistance and extradition

Formal cooperation mechanisms can help investigators obtain overseas records, conduct authorized investigative steps and pursue suspects, subject to domestic law and applicable treaties.

Medicines regulators and forensic laboratories

Product testing, batch verification, manufacturer records and expert evidence can help distinguish falsified products from legitimate products that were improperly stored or diverted.

Effective cooperation should also protect patient confidentiality, lawful research and the rights of accused persons. Information sharing must have a lawful basis, and the collection of evidence must satisfy the requirements of the relevant jurisdiction.

8. Liability, penalties and remedies

Depending on the jurisdiction and facts, enforcement may involve several forms of liability.

1. Criminal liability: Knowingly manufacturing, selling, importing or distributing falsified or prohibited products, where the applicable statute criminalizes that conduct.

2. Regulatory liability: Breaching applicable licence conditions, manufacturing standards, approval requirements, distribution controls or recordkeeping duties.

3. Financial liability: Forfeiture, restitution, compensation or recovery of proceeds where the relevant legal requirements are satisfied.

4. Civil liability: Claims for personal injury, negligence, fraud or other recognized causes of action, subject to proof of duty, causation, damage and applicable defences.

5. Corporate liability: Liability of a company or responsible officers where the relevant statutory requirements for corporate attribution, authorization, consent, connivance or neglect are established.

The legal analysis should distinguish between a seller who knowingly supplies falsified medicines, a distributor who negligently mishandles genuine products, a company whose products were stolen without its involvement, and an innocent purchaser deceived by the seller.

9. Recommended enforcement framework

A legally robust response can be organized into six stages.

Identify and classify the product. Determine whether it is a drug, biological medicine, human-derived material or another regulated item, and identify the applicable approval and licensing requirements.

Preserve evidence lawfully. Secure relevant digital records, transaction information, packaging, shipping documents and physical samples with appropriate documentation and chain of custody.

Verify scientific facts. Obtain qualified laboratory testing and expert analysis of authenticity, composition, contamination, potency and storage integrity where relevant.

Establish attribution and knowledge. Corroborate the alleged seller's identity, role, intent or knowledge, and distinguish deliberate trafficking from innocent possession or administrative failure.

Coordinate across jurisdictions. Use appropriate regulatory, customs, law-enforcement and mutual legal assistance channels, respecting legal safeguards and jurisdictional limits.

Protect affected patients and the public. Consider lawful seizure, recall, health warnings, clinical follow-up and compensation mechanisms, as appropriate to the risk and available evidence.

10. Conclusion

Dark web biologics trafficking exposes a gap between the global reach of online commerce and the territorial nature of criminal law. The central enforcement difficulties are anonymity, product complexity, fragmented supply chains, cross-border evidence, scientific uncertainty and delayed patient harm.

The strongest legal response combines product-specific pharmaceutical regulation, properly authorized digital investigations, forensic verification, financial tracing, international cooperation and proportionate prosecution.

For Indian legal analysis, Arjun Panditrao Khotkar and Anvar P.V. are especially relevant to electronic-evidence principles, while comparative cases such as United States v. Wala and United States v. Gordon illustrate how counterfeit pharmaceutical distribution may be prosecuted. None should be mischaracterized as a direct ruling on dark-web biologics trafficking.

Overall legal principle: Criminal liability should rest on proof of the applicable offence, reliable scientific and digital evidence, and a legally established connection between the accused and the unlawful transaction—not on the use of the dark web alone.

This is a comparative legal overview for academic research, not jurisdiction-specific legal advice. Before citing any authority in a formal pleading or dissertation, verify the full judgment, subsequent treatment and the legislation in force for the relevant proceedings.